A Review on Change Management System in Pharmaceutical Industry
Change control system provides a consistent and well-structured approach towards managing deviations and changes. Changes are unavoidable in a pharmaceutical manufacturing operation. Change management system is a systemic approach adopted by the pharmaceutical industries wherein qualified representatives of appropriate disciplines and personnel review proposed or actual changes that might affect the validated status of facilities, systems, equipment or processes. The change management system includes the implementation plan, installation, verification and the closure of the change control. Changes are classified as critical, major and minor. After the implementation of proposed change, an evaluation of the change should be undertaken to confirm the change objectives are fulfilled and achieved and to make sure that there are no detectable impact on final product quality.
2. Premnath S. Handbook of pharmaceutical quality assurance. Bengaluru: 1st Edition; 2016:102-10.
3. Freeman S. Change management: A far-reaching, comprehensive, and integrated system compliance. Handbook for Pharmaceuticals, Medical Devices, and Biologics. Ed. Carmen Medina. 1st edition. New York: Marcel Dekker; 2004.p.315-46.
4. Ginsbury KS. Global regulations for change management. Journal of GXP Compliance [Internet]. 2008 [cited 2021 Aug 01]; 2212(3):70-75. Available from:
5. Dambrin C, Lambert C, Sponem S. Control and change-analyzing the process of institutionalization. Management Accounting Research [Internet]. 2007 [cited 2021 Aug 01]; 18(2):172-208. Available from:
6. Benefits of Change Management [Internet]. nibusinessinfo;2014 [cited 2021 Aug 01] Available from:
7. Ali H, Gonjare N, D'souza M. Change Management in Pharmaceuticals: The most critical element of Quality Management System. J of Pharmacy Res. [Internet]. 2012 [cited 2021 Aug 01]; 5(7):3706-708. Available from:
8. Sharma D, Sharma V. Regulatory Aspect of Pharmaceutical Change Control System. Journal of Drug Delivery & Therapeutics [Internet]. 2011 [cited 2021 Aug 01]; 1(1):24-31. Available from:
9. International Council on Harmonization of technical requirements for registration of pharmaceutical for human use guidelines, Q 10, 2008 [Internet]. ICH;2014 [cited 2021 Aug 01] Available from:
10. ICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management. Committee for Medicinal Products for Human Use EMA/CHMP/ICH/804273/ 2017;16 [Internet]. EMEA; 2017 [cited 2021 Aug 06] Available from:
11. Water LNH, Kowtna CC. Change control and SUPAC, in Nash RA, Watcher AH. Eds. Pharmaceutical Process Validation. New York: Marcel Dekker; 2003.p. 699-748
12. Pai DR, Kamath KK, Subrahmanyam EVS, Shabaraya AR. Personal Training for Pharmaceutical Industry. Int. J. of Pharm. Quality Assurance [Internet]. 2016 [cited 2021 Aug 06]; 7(3):55-61. Available from:
13. Committee P. Working party on control of medicines and inspections final version of annex 15 to the EU Guide to Good Manufacturing Practice [Internet]. European Commission; 2014 [cited 2021 Aug 06] Available from:
14. Todnem BR. Organizational change management: A critical review. J. of change management. [Internet]. 2005 [cited 2021 Aug 06]; 5(4):369-80. Available from:
https://www.researchgate.net/publication/233604011_ Organizational_ Change_Management_A_Critical_Review.
15. Butcher D. Deviation and Change Control in Pharmaceutical Manufacturing. Master Control GxP Lifeline 2020;10 [Internet]. Mastercontrol; 2020 [cited 2021 Aug 06] Available from:
16. FDA. Center for Drug Evaluation and Research, Guidance for Industry: Immediate Release Solid Oral Dosage Forms. Scale-up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation [SUPAC-IR]. [Internet]. FDA; 1995 Nov [cited 2021 Aug 06] Available from:
17. U.S. Food and Drug Administration, 21 CFR Part 314.70, Supplements and other changes to an Approved Application, Revised as of April 1, 2000. 12. [Internet]. FDA; 2020 Apr 01 [cited 2021 Aug.02]. Available from:
18. U.S. Food and Drug Administration, 21 CFR Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals [Internet]. FDA; 2020 Apr 01 [cited 2021 Aug 02] Available from:
19. Sarisan S, Kayar GG, Gokalp M, Dude UK, Knezevic Z, Dayan N et al., Determination and application of biorelevant dissolution media to meet the in-vivo performance in Valsartan and Chlorthalidone in solid dosage form. Int J Pharm Sci & Res. [Internet]. 2019 [cited 2021 Aug.02]; 10(11):4853- 60. Available from:
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM